Personalized immune cells battle High-Risk leukemia in new trial
NCT ID NCT07053059
Summary
This study is testing whether a personalized cell therapy called obecabtagene autoleucel (obe-cel) can help control high-risk B-cell acute lymphocytic leukemia (ALL) when given after initial chemotherapy. Researchers will enroll about 30 adults with newly diagnosed, high-risk ALL to see if this treatment improves long-term outcomes and is safe. The therapy involves collecting a patient's own immune cells, modifying them to target cancer, and reinfusing them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.